Zenas BioPharma, Inc. Overview
ZBIO market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ZBIO price chart · 1M
- O
- 28.14
- H
- 28.14
- L
- 26.62
- C
- 26.62
- Vol
- 9,173.00
Daily history from Sep 13, 2024
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $28.14
- Previous Close
- $28.44
- Day High
- $28.14
- Day Low
- $26.62
- 52 Week High
- $44.52
- 52 Week Low
- $13.51
- 7 Day Return
- -7.47%
- 30 Day Return
- -1.04%
- 90 Day Return
- -17.92%
- 1 Year Return
- -13.32%
- Daily Notional Volume
- $244.2K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$8.44 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.70 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -11,145.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.50 – $44.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.9B · P/B 8.05 · P/S 1,869.31.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured